

**Draft agenda**  
**50<sup>th</sup> meeting of the Biocidal Products Committee (BPC)**  
**26-27 & 29 February 2024**  
**Meeting is held virtually in Webex**

**Starts on 26 February at 10:30,  
ends on 29 February at 17:00**  
**The time is indicated in Helsinki time.**

**1. – Welcome and apologies**

**2. – Agreement of the agenda**

BPC-A-50-2024\_rev1  
***For agreement***

**3. – Declarations of potential conflicts of interest to agenda items**

**4. – Agreement of the minutes and review of actions from BPC-49**

BPC-M-49-2023  
***For agreement***

**5. – Administrative issues**

**5.1. Administrative issues**

***For information***

**6. – Work programme for BPC**

**6.1. BPC Work Programmes for active substance approval, Union  
authorisation, ED assessment and outlook for BPC**

BPC-50-2024-6.1 A-D  
***For information***

**6.2. Update on active substance approval**

***For information***

**6.3. Update on Union Authorisation processes**

***For information***

**6.4. Update on article 75(1)(g) mandates**

***For information***

**6.5. Dissemination of assessment reports**

***For agreement***

**6.6. Minor update of the Active Substance Working Procedure**

BPC-50-2024-6.6 A

***For agreement***

**6.7. Minor updates to the procedures for minor change applications of Union authorisation and revision of the linguistic check of SPC translations of Union authorisation of some biocidal products**

BPC-50-2024-6.7 A-B

***For agreement***

**7. – Applications for approval of active substances\***

**7.1. Draft BPC opinion on the approval of 2-methyl-4-oxo-3-(prop-2-ynyl)cyclopent-2-en-1-yl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate (Prallethrin) for PT 18**

*Previous discussion: WG-IV-2023*

BPC-50-2024-7.1 A-H

***For adoption***  
**(closed session)**

**7.2. Draft BPC opinion on the approval of Silver zinc zeolite for PT 2, 7, 9**

*Previous discussions: TM-II-2013, TM-IV-2013, WG-III-2015, WG-III-2016, WG-V-2016, WG-V-2017, BPC-27, BPC 28, WG-IV-2023*

BPC-50-2024-7.2 A1,2&3-E

***For adoption***

**7.3. Draft BPC opinion on the renewal of Cholecalciferol for PT14**

BPC-50-2024-7.3 A-C

***For adoption***

**7.4. Evaluation of post-approval data submitted for cypermethrin for PT 18**

*Previous discussion: WG-III-2023*

BPC-49-2023-7.4 A, B1&2-E

***For adoption***  
**(closed session)**

---

\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

## 8. – Union authorisation\*\*

### 8.1. Member state experience in rejecting Union Authorisation

*For information*

### 8.2. Draft BPC opinion on the Union Authorisation of a biocidal product family containing L-(+)-lactic acid for PT 3

*Previous discussion: WG-IV-2023*

BPC-50-2024-8.2 A-E

*For adoption*

### 8.3. Draft BPC opinion on the Union Authorisation of a biocidal product family containing Hydrogen peroxide for PT 2, 4

*Previous discussion: WG-IV-2023*

BPC-50-2024-8.3 A, B, C1&2, D1-3, E

*For adoption  
(closed session)*

### 8.4. Draft BPC opinion on the Union Authorisation of a biocidal product containing N-cyclopropyl-1,3,5-triazine-2,4,6-triamine (Cyromazine) for PT 18

*Previous discussion: WG-IV-2023*

BPC-50-2024-8.4 A-E

*For adoption  
(closed session)*

### 8.5. e-Consultation: PT designation of surface disinfectant in healthcare areas

BPC-50-2024-8.5 A-C

*For discussion*

## 9. – Article 75(1)(g) opinion requests

### 9.1. Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistant *Aspergillus* spp.

*Previous discussion: BPC-46*

*For information*

---

\*\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product family (denoted by E).

**10. - Any other business**

**10.1. Update on progress: Development of in situ guidance**

BPC-50-2024-10.1 A

***For information***

**10.2. Follow up interviews BPC members in October/November**

***For information***

**10.3. Forming a working group for reporting on art 5(2) in the opinion**

***For discussion***

**11. - Action points and conclusions**

**Provisional time schedule for the  
50<sup>th</sup> meeting of the Biocidal Products Committee (BPC)  
Virtual meeting in WebEx**

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

**Monday 26 February: (starts at 10:30 EET/09:30 CET, ends at 17:00 EET/16:00 CET)**

Items 1-5	Opening items and administrative issues
Item 6.1	BPC Work Programmes for active substance approval, Union authorisation, ED assessment and outlook for BPC
Item 6.2	Update on active substance approval
Item 6.3	Update on Union Authorisation processes
Item 6.4	Update on article 75(1)(g) mandates
Item 6.5	Dissemination of assessment reports
Item 6.6	Minor update of the Active Substance Working Procedure
Item 6.7	Minor updates to the procedures for minor change applications of Union authorisation and revision of the linguistic check of SPC translations of Union authorisation of same biocidal products
Item 7.1	Draft BPC opinion on the approval of 2-methyl-4-oxo-3-(prop-2-ynyl)cyclopent-2-en-1-yl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate (Prallethrin) for PT 18 (closed session)

**Tuesday 27 February: (starts at 10:30 EET/09:30 CET, ends at 17:00 EET/16:00 CET)**

Item 7.2	Draft BPC opinion on the approval of Silver zinc zeolite for PT 2, 7, 9
Item 7.3	Draft BPC opinion on the renewal of Cholecalciferol for PT 14
Item 7.4	Evaluation of post-approval data submitted for cypermethrin for PT 18 (closed session)
Item 8.1	Member state experience in rejecting Union Authorisation
Item 8.2	Draft BPC opinion on the Union Authorisation of a biocidal product family containing L-(+)-lactic acid for PT 3

**Thursday 29 February: (starts at 10:30 EET/09:30 CET, ends at 17:00 EET/16:00 CET)**

Item 8.3	Draft BPC opinion on the Union Authorisation of a biocidal product family containing Hydrogen peroxide for PT 2, 4 (closed session)
Item 8.4	Draft BPC opinion on the Union Authorisation of a biocidal product containing N-cyclopropyl-1,3,5-triazine-2,4,6-triamine (Cyromazine) for PT 18 (closed session)
Item 8.5	e-Consultation: PT designation of surface disinfectant in healthcare areas
Item 9.1	Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistant <i>Aspergillus</i> spp.

- Item 10.1 Reporting on development of in situ guidance
- Item 10.2 Follow up interviews BPC members in October/November
- Item 10.3 Forming a working group for reporting on art 5(2) in the opinion
- Item 11 Action points and conclusions

End of meeting

oOo